All-trans retionic ACid in the treatment of myelodysplastic syndromes

G. Visani, P. Tosi, S. Manfroi, E. Ottaviani, C. Finelli, A. Cenacchi, M. Bendandi, S. Tura, Mashiro Imamura, Masharu Kasai, Xiaofan Zhu, Sumiko Kobayashi, Satoshi Hashino, Toshio Higa, Keisuke Sakurada, Masahiro Asaka

Research output: Contribution to journalArticle

Abstract

Myelodysplastic syndromes (MDS) are a group of hematopoietic disorders characterized by uni- or multilineage maturation defects of the bone marrow. Controversial therapeutic results have been obtained using growth factors or differentiating agents such as 134s retinoic acid. In this pilot study we evaluatedthe effects of all-trans retinoic acid (ATRA) in 10 MDS patients (5 male, 5 female). Six patients had refractory anemia (RA), I had refractory anemia with excess of blasts (RAEB), and 3 had refractory anemia with excess of blasts in transformation (RAEB-t). All patients received the same dose of ATRA (45 mg/sqm/day) orally for 6 weeks. A rise in hemoglobin concentration >Ig/dl was observed in 3/10 patients, while 5/10 patients showed an increase in granulocyte count >0.5 × 109/1 without concomitant increase in the percentage of blast cells in the bone marrow. A rise in the platelet count >50 × 109/1 was observed in 1/10 patients. All the effects were transient and maximal responses were obtained by the fourth week of treatment. Thereafter, the peripheral blood counts started todrop again, reaching pre-therapy values by the end of the treatment. This phcnomenon could be attributed either to the exhaustion of an ATRA-responding cell pool, the development of cellular resistance to ATRA or to a reduction of plasma ATRA levels after prolonged treatrncnt. According to our results, it seems that ATRA might have therapeutic efficacy in MDS, particularly if its effect Interleukin-I receptor type I (IL-IR), IL-2 receptor a subunit (IL-2R) and IL-6 receptor a subunit

Original languageEnglish
Pages (from-to)277-280
Number of pages4
JournalLeukemia and Lymphoma
Volume19
Issue number3-4
DOIs
Publication statusPublished - 1995

Keywords

  • All-trans retinoic acid
  • Bone marrow transplantaion
  • Cytokine
  • Cytokine receptor
  • Differetatopm
  • Graft-versus-host disease
  • Myelodysplasia
  • Venooculusive diseae of the liver

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'All-trans retionic ACid in the treatment of myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Visani, G., Tosi, P., Manfroi, S., Ottaviani, E., Finelli, C., Cenacchi, A., Bendandi, M., Tura, S., Imamura, M., Kasai, M., Zhu, X., Kobayashi, S., Hashino, S., Higa, T., Sakurada, K., & Asaka, M. (1995). All-trans retionic ACid in the treatment of myelodysplastic syndromes. Leukemia and Lymphoma, 19(3-4), 277-280. https://doi.org/10.3109/10428199509107898